Patrick F Smith

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5268818/publications.pdf

Version: 2024-02-01

98	3,591	136740	149479
papers	citations	32 h-index	56 g-index

101	101	101	3997
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, The, 2010, 376, 1467-1475.	6.3	313
2	Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors. Clinical Pharmacokinetics, 2001, 40, 893-905.	1.6	183
3	Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine, 2015, 373, 2048-2058.	13.9	183
4	Timing of Antiviral Treatment Initiation is Critical to Reduce SARSâ€CoVâ€2 Viral Load. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 509-514.	1.3	170
5	Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-‹i›O‹/i›-(3â€²,3â€²-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 3574-3581.	1.4	164
6	The Influence of St. Johnâ€™s Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate. Pharmacotherapy, 2004, 24, 1508-1514.	1.2	119
7	Oxaliplatin in Combination With Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer. Journal of Clinical Oncology, 2002, 20, 2844-2850.	0.8	110
8	Treating mammalian bite wounds. Journal of Clinical Pharmacy and Therapeutics, 2000, 25, 85-99.	0.7	102
9	Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. Gastroenterology, 2012, 142, 790-795.	0.6	91
10	Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. PLoS Computational Biology, 2013, 9, e1002959.	1.5	83
11	Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases, 2006, 43, S224-S234.	2.9	81
12	A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. British Journal of Clinical Pharmacology, 2017, 83, 2367-2376.	1.1	79
13	Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers. Pharmacotherapy, 2006, 26, 341-346.	1.2	72
14	Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases, 2006, 43, S235-S246.	2.9	70
15	Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clinical Therapeutics, 2001, 23, 1231-1244.	1.1	60
16	Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine, 2019, 40, 574-582.	2.7	60
17	Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. Journal of Hepatology, 2011, 54, 1130-1136.	1.8	57
18	Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology, 2012, 55, 1030-1037.	3.6	51

#	Article	IF	Citations
19	Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi. Antimicrobial Agents and Chemotherapy, 2005, 49, 1775-1781.	1.4	48
20	Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN Î±-2a/RBV in hepatitis C patients. Journal of Hepatology, 2011, 55, 972-979.	1.8	48
21	Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. EBioMedicine, 2016, 5, 147-155.	2.7	48
22	Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype. Antimicrobial Agents and Chemotherapy, 2008, 52, 1533-1537.	1.4	46
23	Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal on Addictions, 2004, 13, 163-180.	1.3	43
24	Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 473-485.	1.5	43
25	Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2012, 56, 3144-3156.	1.4	41
26	Modelâ€Informed Drug Development for Antiâ€Infectives: State of the Art and Future. Clinical Pharmacology and Therapeutics, 2021, 109, 867-891.	2.3	41
27	Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate. European Journal of Clinical Pharmacology, 2013, 69, 1777-1784.	0.8	40
28	A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.. Clinical Cancer Research, 2006, 12, 1237-1244.	3.2	38
29	Accuracy of Measured Vancomycin Serum Concentrations in Patients with End-Stage Renal Disease. Annals of Pharmacotherapy, 1999, 33, 1329-1335.	0.9	37
30	Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal on Addictions, 2006, 15, 23-34.	1.3	37
31	Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution. Antimicrobial Agents and Chemotherapy, 2012, 56, 271-279.	1.4	37
32	Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. British Journal of Clinical Pharmacology, 2017, 83, 1580-1594.	1.1	36
33	Dosing will be a key success factor in repurposing antivirals for COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 3451-3454.	1.1	34
34	Induction of imatinib metabolism by hypericum perforatum. Blood, 2004, 104, 1229-1230.	0.6	33
35	Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil. Clinical Cancer Research, 2007, 13, 965-971.	3.2	32
36	In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2008, 62, 156-160.	1.3	32

#	Article	IF	Citations
37	Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. Journal of Clinical Lipidology, 2022, 16, 208-219.	0.6	32
38	A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 62, 499-508.	1.1	31
39	Vancomycin-Induced Neutropenia Associated With Fever: Similarities Between Two Immune-Mediated Drug Reactions. Pharmacotherapy, 1999, 19, 240-244.	1.2	30
40	Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagnostic Microbiology and Infectious Disease, 2005, 52, 255-259.	0.8	28
41	Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies. Antimicrobial Agents and Chemotherapy, 2013, 57, 3478-3487.	1.4	26
42	Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochemical Pharmacology, 2007, 73, 1280-1287.	2.0	25
43	Hepatitis C Viral Kinetics. Clinics in Liver Disease, 2013, 17, 13-26.	1.0	25
44	New Modified Fluorescence Polarization Immunoassay Does Not Falsely Elevate Vancomycin Concentrations in Patients With End-Stage Renal Disease. Therapeutic Drug Monitoring, 1998, 20, 231-235.	1.0	25
45	Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation. Therapeutic Drug Monitoring, 2006, 28, 62-66.	1.0	24
46	Gemcitabine and Acute Myocardial Infarction. Angiology, 2006, 57, 367-371.	0.8	24
47	A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology, 2013, 69, 1939-1949.	0.8	23
48	A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrobial Agents and Chemotherapy, 2015, 59, 5388-5395.	1.4	23
49	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1364-1366.	0.6	23
50	Mericitabine and ritonavirâ€boosted danoprevir with or without ribavirin in treatmentâ€naive <scp>HCV</scp> genotype 1 patients: <scp>INFORM</scp>â€<scp>SVR</scp> study. Liver International, 2015, 35, 79-89.	1.9	21
51	Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clinical and Translational Science, 2022, 15, 442-450.	1.5	21
52	Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Fosamprenavir-Ritonavir in Opioid-Dependent Subjects. Pharmacotherapy, 2008, 28, 863-874.	1.2	20
53	Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharmaceutics and Drug Disposition, 2011, 32, 261-275.	1.1	20
54	Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics. Antimicrobial Agents and Chemotherapy, 2013, 57, 3470-3477.	1.4	20

#	Article	IF	Citations
55	Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. Journal of Antimicrobial Chemotherapy, 2019, 74, 442-452.	1.3	20
56	Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon Î±-2a and Ribavirin in Patients With Hepatitis C. Journal of Infectious Diseases, 2011, 204, 601-608.	1.9	19
57	Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics. Clinical Pharmacokinetics, 2012, 51, 457-465.	1.6	19
58	Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2aâ€“Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. Antimicrobial Agents and Chemotherapy, 2014, 58, 1136-1145.	1.4	19
59	Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone. Pharmacotherapy, 2004, 24, 970-977.	1.2	17
60	Effect of saquinavir/ritonavir (1000/100â€ƒmg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addiction Biology, 2009, 14, 321-327.	1.4	16
61	Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin. Clinical Pharmacokinetics, 2013, 52, 805-813.	1.6	16
62	Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemotherapy and Pharmacology, 2003, 51, 376-384.	1.1	15
63	Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion. Journal of Clinical Pharmacology, 2003, 43, 1324-1328.	1.0	15
64	Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 197-207.	1.5	14
65	Capecitabine, Oxaliplatin and Radiotherapy: A Phase IB Neoadjuvant Study for Esophageal Cancer with Gene Expression Analysis. Cancer Investigation, 2009, 27, 193-200.	0.6	14
66	Phase I and pharmacokinetic study of anhydrovinblastine every 3Âweeks in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2003, 51, 227-230.	1.1	13
67	Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Research, 2020, 184, 104763.	1.9	13
68	Absolute Bioavailability and Disposition of (â^') and (+) 2â€²-Deoxy- 3â€²-Oxa-4â€²-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans. Antimicrobial Agents and Chemotherapy, 2000, 44, 1609-1615.	1.4	12
69	Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Molecular Cancer Therapeutics, 2005, 4, 843-854.	1.9	12
70	Danoprevir Monotherapy Decreases Inflammatory Markers in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 3125-3132.	1.4	12
71	Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals. Clinical Pharmacokinetics, 2005, 44, 99-109.	1.6	11
72	Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagnostic Microbiology and Infectious Disease, 2006, 56, 379-386.	0.8	10

#	Article	IF	Citations
73	Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. Clinical Therapeutics, 2014, 36, 2047-2063.e3.	1.1	10
74	Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir. Clinical Pharmacokinetics, 2015, 54, 537-549.	1.6	10
75	Optimizing COVIDâ€19 Candidate Therapeutics: Thinking Without Borders. Clinical and Translational Science, 2020, 13, 830-834.	1.5	10
76	Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naiì¨ve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 3558-3561.	1.4	9
77	Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers. Journal of Pharmacy and Pharmacology, 2013, 66, 23-31.	1.2	9
78	A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. Antiviral Therapy, 2015, 20, 469-477.	0.6	7
79	Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. Travel Medicine and Infectious Disease, 2014, 12, 726-732.	1.5	6
80	Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2006, 57, 73-83.	1.1	5
81	Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARSâ€CoVâ€2. British Journal of Clinical Pharmacology, 2021, 87, 3425-3438.	1.1	5
82	Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males. Antimicrobial Agents and Chemotherapy, 2000, 44, 2816-2823.	1.4	4
83	Beyond Geneticsâ€”Stratified and Personalised Medicines Using Multiple Parameters. Pharmaceuticals, 2010, 3, 1637-1651.	1.7	4
84	Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drugâ€disease modelling for dosing regimen optimization. British Journal of Clinical Pharmacology, 2021, 87, 1359-1368.	1.1	4
85	Effect of Ritonavirâ€Boosted Danoprevir, a Potent Hepatitis <scp>C</scp> Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy. Pharmacotherapy, 2014, 34, 220-226.	1.2	3
86	Applications of Influenza Viral Kinetic Modeling in Drug Development. Current Pharmacology Reports, 2017, 3, 294-300.	1.5	3
87	A Pharmacokinetic/Viral Kinetic Model to Evaluate Treatment of Chronic HCV Infection with a Non-Nucleoside Polymerase Inhibitor. Antiviral Therapy, 2018, 23, 353-361.	0.6	3
88	Two-way interaction study between ritonavirboosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 103-111.	0.3	3
89	Clinical Pharmacology Knowledge, Opportunities and Working Strengths (<scp>CPKNOWS</scp>): a competency model for pursuit of excellence in clinical pharmacology. British Journal of Clinical Pharmacology, 2013, 76, 841-845.	1.1	2
90	Understanding the effect of the <scp>HCV</scp> polymerase inhibitor mericitabine on early viral kinetics in the phase 2 <scp>JUMP</scp>â€<scp>C</scp> and <scp>PROPEL</scp> studies. British Journal of Clinical Pharmacology, 2014, 78, 533-542.	1.1	2

#	Article	IF	Citations
91	Modelling the Interaction between Danoprevir and Mericitabine in the Treatment of Chronic HCV Infection. Antiviral Therapy, 2016, 21, 297-306.	0.6	2
92	A thorough <scp>QTc</scp> study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects. Clinical and Translational Science, 2022, , .	1.5	2
93	Effect of Food on the Pharmacokinetics of (-) and (+) dOTC When Administered as an Oral Racemate. Journal of Clinical Pharmacology, 2002, 42, 658-661.	1.0	1
94	A grapefruit a day for patients infected with hepatitis C?. Hepatology, 2008, 47, 2141-2142.	3.6	1
95	Effect of Ritonavirâ€Boosted Danoprevir, a Potent Hepatitis <scp>C</scp> Virus Protease Inhibitor, on <scp>QTc</scp> Interval in Healthy Subjects: Results from a Thorough <scp>QT</scp> Study. Drug Development Research, 2013, 74, 306-315.	1.4	1
96	Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study. Clinical Pharmacology in Drug Development, 2014, 3, 179-186.	0.8	1
97	The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. Drug Development Research, 2014, 75, 107-113.	1.4	1
98	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. British Journal of Clinical Pharmacology, 2021, 87, 3398-3407.	1.1	1